Related references
Note: Only part of the references are listed.Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples
Francesca Ambrosi et al.
PATHOLOGY RESEARCH AND PRACTICE (2022)
Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID
Rui P. L. Neves et al.
CLINICAL CHEMISTRY (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Factors Influencing Concordance of PD-L1 Expression between Biopsies and Cytological Specimens in Non-Small Cell Lung Cancer
Mohammed S. I. Mansour et al.
DIAGNOSTICS (2021)
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
Alice Indini et al.
CANCERS (2021)
PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature
Mohammed S. I. Mansour et al.
ACTA CYTOLOGICA (2021)
Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer
Lea Sinoquet et al.
CLINICAL CHEMISTRY (2021)
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
Desiree Loreth et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Emerging role of circulating tumor cells in immunotherapy
Alexey Rzhevskiy et al.
THERANOSTICS (2021)
Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer
Bregje M. Koomen et al.
CANCER CYTOPATHOLOGY (2021)
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients
C. Kuempers et al.
VIRCHOWS ARCHIV (2020)
Utility of PD-L1 immunocytochemistry using body-fluid cell blocks patients with non-small-cell lung cancer
Seung GeunDoo Song et al.
DIAGNOSTIC CYTOPATHOLOGY (2020)
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Xiaoming Zhong et al.
MOLECULAR CANCER (2020)
Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
Jasna Metovic et al.
ACTA CYTOLOGICA (2020)
Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients
Claudia Koch et al.
CANCERS (2020)
Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation
Si Kei Lou et al.
ACTA CYTOLOGICA (2020)
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens
Lukas Bubendorf et al.
CANCER CYTOPATHOLOGY (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
Arutha Kulasinghe et al.
CANCERS (2019)
A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer
Akihito Tsunoda et al.
BMC CANCER (2019)
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Melanie Janning et al.
CANCERS (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2019)
Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay
Enrico Munari et al.
CANCER CYTOPATHOLOGY (2019)
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations
Bryce Noll et al.
CANCER CYTOPATHOLOGY (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas
Gilbert Bigras et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer
Arutha Kulasinghe et al.
CANCER MEDICINE (2018)
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
M. Ilie et al.
ANNALS OF ONCOLOGY (2018)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
Birgit G. Skov et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells
Tobias M. Gorges et al.
CLINICAL CHEMISTRY (2016)
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
G. E. Hvichia et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer
Therese Phillips et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
Share Paper
